Aptevo Therapeutics Inc. · NASDAQ (us_market)
Healthcare · Biotechnology · United States
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. Its lead clinical blood cancer candidate is mipletamig that is in Phase 1b/2 clinical trial for the treatment of acute myelogenous leukemia. The company also develops ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for the treatment malignant pleural mesothelioma, non-small cell lung, gastric/gastro-esophageal, head and neck squamous cell carcinoma, pancreatic, renal, ovarian, prostate, breast, cervical, colorectal, endometrial, and bladder cancers; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate to treat multiple solid tumors; APVO442, a preclinical bispecific candidate based on the ADAPTIR-FLEX platform technology for the treatment of multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate to treat prostate cancer. It has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2025-12-04$25.02 RISE2026-03-30$3.96 PEAK2026-04-16$5.61 133d | -84.2% 116d | Missed | Missed | — | — | +41.7% 17d | Missed |
DROP2025-10-09$31.68 RISE2026-02-05$6.01 PEAK2026-02-26$7.35 140d | -81.0% 119d | Missed | Missed | — | — | +22.3% 21d | Missed |
DROP2025-05-22$108.00 RISE2025-10-01$25.02 PEAK2025-10-07$31.68 138d | -76.8% 132d | Missed | Missed | — | — | +26.6% 6d | Missed |
DROP2025-02-06$1,551.60 RISE2025-06-17$50.76 PEAK2025-06-18$92.34 132d | -96.7% 131d | Missed | Missed | — | — | +81.9% 1d | Missed |
DROP2024-08-15$5,794.20 RISE2024-12-16$1,396.80 PEAK2025-01-07$1,861.20 145d | -75.9% 123d | Missed | Missed | — | — | +33.2% 22d | Missed |
DROP2024-06-06$11,295.36 RISE2024-10-14$1,878.12 PEAK2024-10-22$4,715.28 138d | -83.4% 130d | Missed | Missed | — | — | +151.1% 8d | Missed |
DROP2024-02-29$99,633.60 RISE2024-07-05$3,889.44 PEAK2024-07-17$7,738.92 139d | -96.1% 127d | Missed | Missed | — | — | +99.0% 12d | Missed |
DROP2023-12-22$111,941.28 RISE2024-04-25$9,057.60 PEAK2024-05-07$15,451.20 137d | -91.9% 125d | Missed | Missed | — | — | +70.6% 12d | Missed |
DROP2023-09-08$240,292.80 RISE2024-01-16$85,567.68 PEAK2024-02-29$99,633.60 174d | -64.4% 130d | Missed | Missed | — | — | +16.4% 44d | Missed |
DROP2023-04-25$1,178,020.75 RISE2023-08-15$216,849.59 PEAK2023-08-31$257,875.20 128d | -81.6% 112d | Missed | Missed | — | — | +18.9% 16d | Missed |
DROP2022-12-12$2,291,572.75 RISE2023-03-23$1,019,779.19 PEAK2023-04-03$1,219,046.38 112d | -55.5% 101d | Missed | Missed | — | — | +19.5% 11d | Missed |
DROP2022-08-15$2,690,107.25 RISE2022-12-19$1,172,160.00 PEAK2023-01-19$1,488,643.25 157d | -56.4% 126d | Missed | Missed | — | — | +27.0% 31d | Missed |
DROP2022-08-15$2,690,107.25 RISE2022-10-20$1,564,833.63 PEAK2022-12-12$2,291,572.75 119d | -41.8% 66d | Missed | Missed | — | — | +46.4% 53d | Missed |
DROP2022-03-24$4,079,116.75 RISE2022-06-16$1,910,620.75 PEAK2022-08-15$2,690,107.25 144d | -53.2% 84d | Missed | Missed | — | — | +40.8% 60d | Missed |
DROP2022-01-03$4,934,793.50 RISE2022-05-09$2,074,723.25 PEAK2022-06-08$3,328,934.50 156d | -58.0% 126d | Missed | Missed | — | — | +60.5% 30d | Missed |
1–15 / 24 1 / 2 | |||||||
No scored news yet for a sentiment trend.
https://patentcenter.uspto.gov/applications/16871597/ifw/docshttps://x.com/PatentGrants/status/2059725536650547305
Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform
Aptevo Therapeutics (APVO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Mipletamig continues to perform, delivers 87% clinical benefit and 81% remission in frontline AML, with no CRS in frontline patientsExecutive leadership transition complete. Jeff Lamothe appointed...
The Company is on track to complete the Phase 1b dose-optimization trial and select the recommended Phase 2 dose (RP2D) this year. As with the current study, the Phase 2 trial will dose mipletamig in combination with
Program Enters Final Stage of Dose OptimizationData Continue to Demonstrate Strong Clinical Activity and Favorable Safety Across an Expanding Frontline Dataset SEATTLE, WA / ACCESS Newswire / May 6,...
Aptevo Therapeutics (APVO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Aptevo Therapeutics (NASDAQ:APVO) reported quarterly losses of $(6.23) per share which beat the analyst consensus estimate of $(8.10) by 23.09 percent. This is a 97.38 percent increase over losses of $(237.60) per share
The market is filled with gapping stocks in Tuesday's session. Let's discover which stocks are showing gap-ups and gap-downs.
As the US market prepares to open on Tuesday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
Frontline patient outcomes are making the case for mipletamig to enhance standard-of-care therapy alongside venetoclax + azacitidineSEATTLE, WA / ACCESS Newswire / March 10, 2026 / Aptevo Therapeutics Inc.
Clinical progress, pipeline expansion, and operational momentum underpin leadership continuity as the Company advances into 2026 and beyond SEATTLE, WA / ACCESS Newswire / February 3, 2026 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage ...
Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today
Together with cash on hand, the fully leveraged facility extends Aptevo's funding runway into 2029, enabling achievement of key clinical and preclinical milestones SEATTLE, WA / ACCESS Newswire / January 9, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO), ...
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| APVO | -0.20% | -30.75% | -47.93% | -94.22% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -3.17% | -25.03% | -44.49% | -106.91% |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-05-13 | -5.60 | -6.41 | -14.46% |
| 2025-11-06 | -37.62 | -40.14 | -6.70% |
| 2025-08-11 | -1497.60 | -151.20 | +89.90% |
| 2025-05-15 | -1515.60 | -1580.40 | -4.28% |
| 2025-02-14 | -2790.00 | -3218.40 | -15.35% |
| 2024-11-07 | -7592.40 | -6393.60 | +15.79% |
| 2024-08-08 | -25707.61 | -22244.40 | +13.47% |
| 2024-05-08 | -171095.43 | -132534.03 | +22.54% |
| 2024-03-05 | -240292.56 | -86095.07 | +64.17% |
| 2023-11-14 | -439559.56 | -293039.71 | +33.33% |
| 2023-08-10 | -656408.94 | -720877.68 | -9.82% |
| 2023-05-11 | -638826.56 | -652892.47 | -2.20% |
| 2023-03-30 | -914283.89 | -619251.51 | +32.27% |
| 2022-11-10 | -890840.71 | -899045.82 | -0.92% |
| 2022-08-11 | -779485.62 | -1087470.35 | -39.51% |
| 2022-05-12 | -673991.33 | -931866.27 | -38.26% |